Company Description
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally.
The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions.
The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands.
The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984.
Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
| Country | United States |
| Founded | 1969 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 60,000 |
| CEO | Rainer Blair |
Contact Details
Address: 2200 Pennsylvania Avenue N.W., Suite 800W Washington, District of Columbia 20037-1701 United States | |
| Phone | 202 828 0850 |
| Website | danaher.com |
Stock Details
| Ticker Symbol | DHR |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000313616 |
| CUSIP Number | 235851102 |
| ISIN Number | US2358511028 |
| Employer ID | 59-1995548 |
| SIC Code | 3823 |
Key Executives
| Name | Position |
|---|---|
| Christopher Paul Riley | Executive Vice President of Biotechnology Group and Chief Executive Officer of Cytiva |
| Rainer M. Blair | President, Chief Executive Officer and Director |
| Steven M. Rales | Co-Founder and Chairman |
| Mitchell P. Rales | Co-Founder and Director |
| Dr. Jose-Carlos Gutierrez-Ramos Ph.D. | Senior Vice President and Chief Science Officer |
| Matthew R. McGrew | Executive Vice President |
| Julie Sawyer Montgomery | Executive Vice President of Diagnostics Platform |
| Matthew E. Gugino C.F.A., CPA | Executive Vice President and Chief Financial Officer |
| Christopher M. Bouda | Vice President and Chief Accounting Officer |
| Dr. Martin Stumpe Ph.D. | Chief Technology and AI Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 25, 2026 | ARS | Filing |
| Mar 25, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 25, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 18, 2026 | 25-NSE | Filing |
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 19, 2026 | 144 | Filing |
| Feb 17, 2026 | 8-K | Current Report |
| Feb 10, 2026 | 8-K | Current Report |
| Jan 30, 2026 | SCHEDULE 13G/A | Filing |